**14th International Conference on Osteogenesis Imperfecta**
**30 August – 2 September 2022, Sheffield, UK**
**Posters**

P1
Significant modifiable risk factors for bone health in patients with osteogenesis imperfecta; the importance of lateral thinking.
**Artemis Doulgeraki** (Athens, Greece)

P2
Effect of bisphosphonate treatment on oral health status of children and adolescents with osteogenesis imperfecta
**Artemis Doulgeraki** (Athens, Greece)

P3
Identification of modifier genes underlying intra-familial phenotypic variability in zebrafish OI models using whole exome sequencing and linkage analysis
**Tamara Jarayseh** (Ghent, Belgium)

P4
Genetic analysis of Osteogenesis Imperfecta in Brazil
**Temis Felix** (Porto Alegre, Brazil)

P5
Characteristic modes of failure in single entry telescopic rods: a combined 2 centre experience
**India Cox** (Bristol, UK)

P6
Spine care in osteogenesis imperfecta from a distance: single center experience
**Jeanne Franzone** (Wilmington, USA)

P7
3D image registration marginally improves short-term in-vivo precision of high resolution peripheral quantitative CT images from adults with osteogenesis imperfecta compared to cross-sectional-area registration
**Seyedmahdi Hosseinitabatabaei** (Montreal, Quebec)

P8
Generation of Osteogenesis imperfecta stem cell bioresource to decipher disease mechanism and aid drug discovery
**Chiara F Sander** (Sheffield, UK)

P9
Oral health related quality of life in children with Osteogenesis Imperfecta of different ethnic backgrounds
**Jasmine May Cachia Mintoff** (London, UK)

P10
Bleeding assessment in 195 patients with Osteogenesis Imperfecta
**Koert Gooijer** (Zwolle, Netherlands)

P11
Mechano-regulation of bone formation and mineralization in healthy and type XI Osteogenesis Imperfecta patient-specific 3D bone organoids
**Julia Griesbach** (Zürich, Switzerland)

P12
Should Osteogenesis Imperfecta be Labeled as a Low Bone Mass Condition?
**Cathleen Raggio** (New York, USA)

P13
Surgical Correction of Skeletal Malocclusion in Osteogenesis Imperfecta
**Joseph Napoli** (Philadelphia, USA)

P14
Assessing the Safety and Efficacy of Tranexamic Acid Usage in Osteogenesis Imperfecta Patients Undergoing Femoral Rodding
**Maegen Wallace** (Omaha, USA)

P15
Therapeutic use of Indomethacin in Osteogenesis Imperfecta Type V
**James Law** (Birmingham, UK)

P16
Quality of life in Osteogenesis Imperfecta: evaluation of the content validity of the OIQoL questionnaire in an international cohort.
**Claire Hill** (Sheffield, UK)

P17
What are the perceived therapy needs of adults living with Osteogenesis Imperfecta? A focus group study.
**Sophie Barlow** (Stanmore, UK)

P18
A service evaluation examining the clinical application of the; Bleck, Brief Assessment of Motor Function Lower Limb and the Screening Tool for Everyday Mobility and Symptoms (STEM) in the functional assessment of children aged 6-18 years who have Osteogenesis Imperfecta
**Carrie Marr** (Sheffield, UK)

P19
Insight into the bone mechanism of CRTAP-null osteoblasts
**Aileen Barnes** (Bethesda, USA)

P20
Severe Obesity in Osteogenesis Imperfecta - What are the Treatment Options?
**Jannie Dahl Hald** (Aarhus, Denmark)

P21
Crispant analysis in zebrafish as a tool for rapid functional screening of disease-causing genes for Osteogenesis Imperfecta.
**Sophie Debaenst** (Ghent, Belgium)

P22
"O.I. wish orthopaedic surgeons had better strategies to help with..." - results of a patient and parent-based survey
**Maegen Wallace** (Omaha, USA)

P23
Physical activity of children with osteogenesis imperfecta during the period of immobilization (fractures) and during the «light» period (period of full functioning)
**Nadezhda Epishina** (St Petersburg, Russia)

P24
Investigating the transition from paediatric to adult services and the management of ongoing care of adults for osteogenesis imperfecta: A qualitative study
**Chloe Morgan** (Swansea, UK)

P25
Service evaluation reviewing the application of the Bayley Scale of Infant and Toddler development in children with severe, complex and atypical Osteogenesis Imperfecta.
**Carrie Marr** (Sheffield, UK)

P26
Cross-centre psychology collaboration on the adaptation of young person 'tree of life' narrative therapy groups to online during the COVID-19 pandemic, as part of the NHS England Osteogenesis Imperfecta National Service.
**Rebecca Jones** (Sheffield, UK)

P27
Cardiovascular characteristics and abnormalities in patients with Osteogenesis Imperfecta: a systematic review
**Sara Verdonk** (Amsterdam, The Netherlands)

P28
Molecular characterization of a newly reported MBTPS2 variant in a fetus affected with severe Osteogenesis Imperfecta
**Giulio Marcionelli** (Zurich, Switzerland)

P29
Studies of OI Patient and Murine Osteoblasts to Investigate Phenotypic Variability of Dominant Osteogenesis Imperfecta
**Milena Jovanovic** (Bethesda, USA)

P30
A new X-linked PLS3 gene variant identified in a patient with osteogenesis imperfecta
**Petar Brlek** (Zagreb, Croatia)

P31
Genotype-phenotype correlation and effects of bisphosphonates in rare forms of osteogenesis imperfecta : a retrospective study
**Maëlle-Charlotte Charpié** (Paris, France)

P32
Pulmonary Complications in Osteogenesis Imperfecta Type III

**Hollis Chaney** (Washington, DC, USA)

P33
Port-a-Cath Placement in Pediatric Patients with Osteogenesis Imperfecta Requiring Long-Term Vascular Access
**Maegen Wallace** (Omaha, USA)

P34
Intramedullary canal sclerosis as a result of prolonged bisphosphonate therapy in children with osteogenesis imperfecta type III and IV
**Darko Antičević** (Zagreb, Croatia)

P35
Tibial Rodding Challenges and Nailing Technique Choice in Children with Osteogenesis Imperfecta and Narrow Intramedullary Canals Using the "Telescoping Principles": A Narrative Review and Expert Opinion
**Alice Tao Ran Guo** (Montreal, Quebec, Canada)

P36
Bone microarchitecture in osteogenesis imperfecta assessed with high-resolution peripheral quantitative CT
**Melissa Bevers** (Venlo, The Netherlands)

P37
Early intervention program for children with OI. 5 years of experience of the Center for Inborn Pathology GMS Clinic
**Natalia Belova** (Moscow, Russia)

P38
Stiff hips in patients with Osteogenesis Imperfecta : a providential femoral neck fracture
**Marine de Tienda** (Paris, France)

P39
Tibia sliding elastic nailing technique in moderate-to-severe Osteogenesis Imperfecta :long-term outcomes
**Marine de Tienda** (Paris, France)

P40
Laboratory assessment in patients with the highest bleeding scores on the Self bleeding assessment tool out of 195 patients with Osteogenesis Imperfecta
**Koert Gooijer** (Zwolle, Netherlands)

P41
Understanding the Physical Well-being of Adults with Osteogenesis Imperfecta
**Kathleen Montpetit** (Montreal, Canada)

P42
Treatment response in Osteogenesis imperfecta - Two-year retrospective analysis of paediatric patients treated with bisphosphonates
**Mirko Rehberg** (Cologne, Germany)

P43
Relative larger Aortic Root Diameter in Osteogenesis Imperfecta Type 3 compared to type 1 and 4
**Koert Gooijer** (Zwolle, Netherlands)

P44
Tooth size in individuals with osteogenesis imperfecta
**Henri Tuurala** (Helsinki, Finland)

P45
Implementation of an Osteogenesis imperfecta patient registry to investigate clinical spectrum and genotype-phenotype correlations in OI
**Timothée Ndarugendamwo** (Zürich, Switzerland)

P46
The Fate of Bent Telescopic Rods in Children with Osteogenesis Imperfecta: Do All Bent Rods Need to be Revised?
**David Fralinger** (Wilmington, USA)

P47
Altered bone healing mechanoresponse exhibited by mouse models of osteogenesis imperfecta
**David Bertrand** (Montreal, Canada)

P48
Ophthalmological screening guidelines for individuals with osteogenesis imperfecta : a scoping review
**Sarah Moussa** (Montreal, Canada)

P49
Oral health related quality of life in adults with osteogenesis imperfecta, in Spain
**Amira Elfituri** (Madrid, Spain)

P50
Lack of psychosocial intervention assessment in OI: a scoping review
**Marie-Catherine Mongenot** (Westmount, Canada)

P51
Ifitm5/BRIL p.S42L murine model for atypical type VI OI has elevated serum alkaline phosphatase and disordered bone matrix but decreased bone cell function
**Gali Guterman-Ram** (Bethesda, USA & Haifa, Israel)

P52
Experience, problems and prospects of development of the program of diagnostics and treatment of osteogenesis imperfecta in children in the Republic of Kazakhstan.
**Dossanova Assem** (Nur-Sultan, Kazakhstan)

P53
Clinical management of the adult patient with Osteogenesis Imperfecta
**Arjan Harsevoort** (Zwolle, Netherlands)

P54
Patient Reported Experience Of Clinical Care Of Osteogenesis Imperfecta (OI) During The COVID-19 Pandemic
**Coreen Kelday** (Dundee, UK)

P55
A Dual centre transition clinic for young people with mild, moderate and severe Osteogenesis Imperfecta
**Martyn Dudley** (London, UK)

P56
Genetics of Rare Skeletal Disorders among Pakistani Consanguineous Families
**Mehran Kausar** (Gilgit, Pakistan)

P57
Prevalence and Hospital Admissions in Patients With Osteogenesis Imperfecta in The Netherlands: A Nationwide Registry Study
**Silvia Storoni** (Amsterdam, Netherlands)

P58
The European Registry for Rare Bone and Mineral Conditions (EuRR-Bone): Results of a Survey on Osteogenesis Imperfecta
**Ana Luisa Priego Zurita** (Leiden, Netherlands)

P59
How we made an Impact – The role of Patient Advocacy Groups in recruitment to surveys on rare conditions
**Ingunn Westerheim** (Oslo, Norway)

P60
Sleeping Compression - Lengthening Nail; Off-label use for treatment of non union then lengthening in Osteogenesis Imperfecta patient
**Yasser Elbatrawy** (Cairo, Egypt)

P61
Skull fractures, cervical spine fractures and intracranial injuries in children with Osteogenesis Imperfecta: a cohort study
**Georgina Williams** (London, UK)

P62
Long-Term Results of Initial and Reoperation Surgeries with Fassier-Duval Intramedullary Rods in Femurs and Tibias of Children with Osteogenesis Imperfecta
**Maegen Wallace** (Omaha, USA)

P63
Impact of pandemic on self-report measures for children with Osteogenesis Imperfecta(OI): a preliminary look
**Maureen Donohoe** (Wilmington, USA)

P64
'In-Out-In' K-wires sliding technics in severe tibial deformities of osteogenesis imperfecta

**Tristan Langlais** (Paris, France)

P65
What's in a Name? Prevalence of Metaphyseal Fractures in Children with Osteogenesis Imperfecta in the First Two Years of Life
**Ella Riley** (Sheffield, UK)

P66
Evidence for Metaphyseal Fractures Typical of Abuse in Osteogenesis Imperfecta: A Systematic Review
**Ella Riley** (Sheffield, UK)

P67
Bone Mass, Density, Geometry and Stress-Strain Index in Adults with Osteogenesis Imperfecta Type I, and their Associations with Physical Activity and Muscle Function Parameters
**Marie Coussens** (Ghent, Belgium)

P68
Typing with OI Type 5
**Zoe Bowman Bayles** (London, UK)

P69
Gene expression profiling of fetal mesenchymal stem cells during osteogenic differentiation
**Emine Begum Gencer-Oncul** (Stockholm, Sweden)

P70
Effect of Blood Flow Restriction Training on Bone, Muscle, Pain, and Fatigue in Adults with Osteogenesis Imperfecta type I: a Protocol Proposal of a Randomized Controlled Clinical Trial
**Marie Coussens** (Ghent, Belgium)

P71
Muscle Function Parameters in Adults with Osteogenesis Imperfecta type I: Preliminary Results
**Marie Coussens** (Ghent, Belgium)

P72
WNT1-related Osteogenesis imperfecta Type 15 and intramembranous calcification: subtle skull vault mineralisation defect only evident on 3D CT head.
**Christine Burren** (Bristol, UK)

P73
The Methodological Approaches Used to Understand the Psychosocial Experiences Of Parents of Children With Osteogenesis Imperfecta: A Review
**Yu Chen Shi** (Montreal, Canada)

P74
The Osteogenesis Imperfecta Variant Database: current state
**Dimitra Micha** (Amsterdam, Netherlands)

P75
Engaging the osteogenesis imperfecta (OI) community in patient centered outcomes research
**Laura Tosi** (Washington DC, USA)

P76
5-years experience of telescopic rods surgery for osteogenesis imperfecta patients in Russia
**Alexey Rykunov** (Moscow, Russia)

P77
The London Osteogenesis Imperfecta Team – Taking a Psychosocial Approach
**Charlotte Barran** (London, UK)

P78
A feasibility study exploring the suitability of the Bayley Scale of Infant and Toddler Development in assessing children from 16 days to 42 months with Osteogenesis Imperfecta who are under the care of the Metabolic Bone Team at Sheffield Children's NHS Foundation Trust
**Carrie Marr** (Sheffield, UK)

P79
Upper limb function in osteogenesis imperfecta: a scoping review
**Jasmine Rocci** (Oakville, Canada)

P80
Using virtual communication for rapid dissemination of COVID-19 information to patients with osteogenesis imperfecta
**Laura Tosi** (Washington, DC, USA)

P81
Quality of life and coping strategies in adults with OI
**Ceú Barreiros** (Lisbon, Portugal)

P82
Technique of telescopic nailing of the femur by retrograde approach (FRA) in patients with osteogenesis imperfecta: clinical and radiological results.
**Zagorka Pejin** (Paris, France)

P83
Ability of Radiofrequency Echographic Multispectrometry in the assessment of bone mineral density in subjects with Osteogenesis Imperfecta
**Antonella Al Refaie** (Siena, Italy)

P84
The Severe Mouse Model of Osteogenesis Imperfecta Exhibits Compromised Cardiac Function
**Brittany Lafaver** (Columbia, USA)

P85
Gene expression signatures in bone and heart tissue of a Col1a1+/Mov13 mice identify it as a challenging animal model for mild Osteogenesis Imperfecta
**Lidiia Zhytnik** (Amsterdam, Netherlands & Tartu, Estonia)

P86
Vertebral fractures in Osteogenesis imperfecta with COL1A1 and COL1A2-mutations
**Bianca Link** (Zurich, Switzerland)

P87
Patient osteoblast model for Osteogenesis Imperfecta using induced mesenchymal stem cells
**Lauria Claeys** (Amsterdam, Netherlands)

P88
Unfractured Care: Transforming Treatment Goals for the Infant with Severe Osteogenesis Imperfecta
**Cristina McGreal** (Wilmington, USA)

P89
Cardiovascular involvement in Osteogenesis Imperfecta - a Portuguese nation-wide cohort study (OI&Heart Study)
**Ceu Barreiros** (Sacavém, Portugal)

P90
Prevalence of tinnitus in adults with osteogenesis imperfecta
**Temis Felix** (Porto Alegre, Brazil)

P91
Landscape of Osteogenesis imperfecta in Brazil: data from the Brazilian Rare Disease Network
**Temis Felix** (Porto Alegre, Brazil)

P92
Using the Bayley Scales of Infant and Toddler Development to assess fine and gross motor skills in young children with severe Osteogenesis Imperfecta
**Emilie Hupin** (London, UK)

P93
Hearing in Osteogenesis imperfecta: a phenotype/genotype analysis
**Temis Felix** (Porto Alegre, Brazil)

P94
Defining Pathomechanisms and Unique and Common Molecular Signatures of MBTPS2 Osteogenesis Imperfecta
**Pei Jin Lim** (Zurich, Switzerland)

P95
Therapeutic Management of Olecranon Fractures in Paediatric Osteogenesis Imperfecta
**Lisa Mills** (Bristol, UK)

P96
Audiological follow up in Osteogenesis Imperfecta
**Temis Felix** (Porto Alegre, Brazil)

P97
Traumatic and non-traumatic cervical spine pathology in Severe, Complex and Atypical Osteogenesis Imperfecta
**Catherine DeVile** (London, UK)

P98
Proteomic analysis of the vertebral column in dominant OI zebrafish models to reveal biomarkers for phenotypic outcome
**Andy Willaert** (Gent, Belgium)

P99
Promoting Inclusion in Physical Education for Children with Osteogenesis Imperfecta: Preliminary Findings and Input Warranted for Guideline Creation
**Galil Osman** (Montreal, Canada)

P100
Osteogenesis Imperfecta Clinic Implementation of patient reported outcome measures (PROM): Implications, Pitfalls, Strategies, and Progress
**Maureen Donohoe** (Wilmington, USA)

P101
Evaluation of Radiolucent Lesions in Cortices of Long Bones in Osteogenesis Imperfecta Patients
**Carolyn Cook** (Chicago, USA)

P102
Design and Development of an E-Health Program for Youth with Osteogenesis Imperfecta – Teens OI
**Raissa Passos dos Santos** (Montreal, Canada)

P103
Skeletal Muscle Mitochondria Function in Osteogenesis Imperfecta Murine and G610C Mouse Models
**Tara Crawford** (Columbia, USA)

P104
Modification of the Osteogenesis Imperfecta Quality of Life Scale - Paediatric version (OIQoL-P) and Development of a Parent-Report version.
**Claire Hill** (London, UK)

P105
WHO-ICF Based Outcomes following Posterior Spinal Fusion with Instrumentation in a Child with OI Type III and Scoliosis- A Five-Year Follow-up
**Frances Baratta-Ziska** (New York, USA)

P106
Clinical and functional characterization of Osteogenesis Imperfecta Type XV: Single-centre Chinese Cohort
**Michael To** (Hong Kong, China)

P107
A retrospective review of 496 orthopedic surgeries in 223 Chinese patients of osteogenesis imperfecta
**Michael To** (Hong Kong, China)

P108
Clinical features and molecular characterization of Chinese patients with type XI osteogenesis imperfecta

**Michael To** (Hong Kong, China)

LM1
Self-perception on quality of life of children and adolescents with Osteogenesis Imperfecta attended in a University Hospital
**Leilah Alves** (Salvador-Ba, Brazil)

LM2
Type I collagen homotrimer exacerbates the impairment of bone structural properties caused by the osteogenesis imperfecta murine mutant allele, despite not itself causing bone fragility
**Elizabeth Laird** (Lowton, UK)

LM3
The Col1a2 +/G610C mutation causing osteogenesis imperfecta aggravate high-calorie diet-induced insulin resistance and bone deterioration in mice
**Noam Levaot** (Beer Sheva, Israel)

LM4
Osteogenesis imperfecta zebrafish models to test a new combined pharmacological approach
**Antonella Forlino** (Pavia, Italy)

LM5
Orbit: a randomized, double-blind, placebo-controlled, Phase 2/3 Study to assess the efficacy and safety of Setrusumab in pediatric and young adult participants with osteogenesis imperfecta
**Michael Ominsky** (Novato, USA)

LM6
Use of analgesics in patients with osteogenesis imperfecta in Denmark – a nationwide register-based cohort study
**Lars Folkestad** (Odense, Denmark)

LM7
Rigid intramedullary nailing of lower limb segments in adolescents with metabolic bone disease
**Charlene Chin See** (Sheffield, UK)

LM8
Chronic pain in adults with OI, its relationship with personality and the mediating role of assessment: a descriptive study.
**Rubén Muñoz Cortés** (Valencia, Spain)

LM9
Osteoporosis-pseudoglioma syndrome (OPPG) in two Bulgarian girls with c.2409_2503+79del mutation in LRP5 gene
**Veselin Boyadzhiev** (Varna, Bulgaria)

LM10
Microtensile properties of dry human bone extracellular matrix from individuals with Osteogenesis Imperfecta are not inferior to healthy controls
**Michael Indermaur** (Bern, Switzerland)

LM11

Natural history of fractures in children and adolescents with osteogenesis imperfecta type 1: A study from Western Australia
**Kiranjit Joshi** (Nedlands, Australia)

LM12
Results of telescopic nailing in children with osteogenesis imperfecta after minimum five-year follow-up
**Ozan Ali Erdal** (Istanbul, Turkey)

LM13
Effects of Losartan on Transforming-Growth-Factor-$\beta$ and Angiotensin pathways in Osteogenesis Imperfecta
**Mai Morita** (Sheffield, UK)

LM14
Osteogenesis Imperfecta type VII: clinical variability and novel variants in CRTAP
**André Travessa** (Lisbon, Portugal)

LM15
Recurrent upper limb fractures: impact on quality of life and management challenges in two children with severe osteogenesis imperfecta
**Emilie Hupin** (London, UK)

LM16
Investigating mutations that cause osteogenesis imperfecta using molecular dynamics
**Michael Jones** (Liverpool, UK)